Completed × NIH × Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative × Clear all
NCT00060021 2015-04-30

Acupuncture in Treating Mucositis-Related Pain Caused by Chemotherapy in Patients Undergoing Stem Cell Transplantation

National Cancer Institute (NCI)

Phase NA Completed
NCT00019656 2015-04-29

Perifosine in Treating Patients With Refractory Solid Tumors or Hematologic Cancer

National Cancer Institute (NCI)

Phase 1 Completed
NCT00381550 2015-01-06

3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia

National Cancer Institute (NCI)

Phase 2 Completed
35 enrolled 8 charts
NCT00351975 2014-12-23

Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases

National Cancer Institute (NCI)

Phase 1 Completed
56 enrolled
NCT01231919 2014-04-29

MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia

National Cancer Institute (NCI)

Phase 1 Completed
45 enrolled
NCT00005863 2013-12-19

Combination Chemotherapy With or Without Filgrastim and/or Tretinoin in Treating Patients With Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 3 Completed
NCT00005823 2013-12-18

Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

National Cancer Institute (NCI)

Phase 3 Completed
2,000 enrolled
NCT00049686 2013-07-18

VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome

National Cancer Institute (NCI)

Phase 1 Completed
NCT00064090 2013-07-18

3-AP and Cytarabine in Treating Patients With Hematologic Cancer

National Cancer Institute (NCI)

Phase 1 Completed
NCT00045006 2013-05-30

Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer

National Cancer Institute (NCI)

Phase 1 Completed
NCT00073944 2013-05-30

BCX-1777 in Treating Patients With Refractory Cancer

National Cancer Institute (NCI)

Phase 1 Completed
NCT00357305 2013-05-03

Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders

National Cancer Institute (NCI)

Phase 1 Completed
25 enrolled
NCT00060372 2013-03-27

Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer

National Cancer Institute (NCI)

Phase 1 Completed
21 enrolled
NCT00569283 2013-03-26

Donor Natural Killer Cell Infusion in Preventing Relapse or Graft Failure in Patients Who Have Undergone Donor Bone Marrow Transplant

National Cancer Institute (NCI)

Phase 1 Completed
18 enrolled
NCT00627666 2013-03-26

Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematological Cancer

National Cancer Institute (NCI)

Phase 2 Completed
52 enrolled
NCT00114257 2013-02-11

Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders

National Cancer Institute (NCI)

Phase 1 Completed
36 enrolled
NCT00064311 2012-03-08

Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
NCT00042822 2011-05-17

FR901228 in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Non-Hodgkin's Lymphoma

National Cancer Institute (NCI)

Phase 2 Completed
NCT00806767 2011-05-17

Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological Cancer

National Cancer Institute (NCI)

Phase 2 Completed
82 enrolled